117 HR 5540 IH: Cosmetic Safety for Communities of Color and Professional Salon Workers Act of 2021
U.S. House of Representatives
2021-10-08
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

I117th CONGRESS1st SessionH. R. 5540IN THE HOUSE OF REPRESENTATIVESOctober 8, 2021Ms. Schakowsky (for herself and Ms. Blunt Rochester) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on Education and Labor, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concernedA BILLTo amend the Public Health Service Act and the Federal Food, Drug, and Cosmetic Act with respect to cosmetic safety, with an emphasis on communities of color and professional salon workers, and for other purposes.1.Short titleThis Act may be cited as the Cosmetic Safety for Communities of Color and Professional Salon Workers Act of 2021.2.Table of contentsThe table of contents of this Act is as follows:Sec. 1. Short title.Sec. 2. Table of contents.Sec. 3. Research on health disparities impacting communities of color.Sec. 4. Research on health concerns impacting professional nail, hair, and beauty salon workers.Sec. 5. Support for creating safer alternatives.Sec. 6. Professional salon product ingredient disclosure in labeling and on websites.Sec. 7. Translation of and access to safety data sheets.Sec. 8. Interagency Council on Cosmetic Safety.Sec. 9. Inclusion of communities of color in ingredient review.3.Research on health disparities impacting communities of colorPart P of title III of the Public Health Service Act (42 U.S.C. 280 et seq.) is amended by adding at the end the following:399V–7.Research on health disparities related to cosmetics impacting communities of color(a)In generalThe Secretary shall—(1)conduct, or award grants for, research relating to basic, epidemiological, and social scientific investigations into—(A)the chemicals that are linked to adverse health effects and most commonly found in cosmetics marketed to women and girls of color, including beauty, personal hygiene, and intimate care products;(B)the use of cosmetics containing such chemicals by women and girls of color across their lifespans; or(C)the specific adverse health effects experienced by women and girls of color from exposure to unsafe chemicals present in cosmetics used by them; and(2)disseminate the results of the investigations conducted or supported under paragraph (1) to help communities identify and address potentially unsafe chemical exposures in the use of cosmetics.(b)ReportNot later than 5 years after awarding the first grant under subsection (a), the Secretary shall make publicly available and submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report on the results of the investigations conducted or supported under subsection (a), including—(1)summary findings on—(A)marketing strategies, product categories, and specific cosmetics containing chemicals linked to adverse health effects; and(B)the demographics of the populations marketed to and using these cosmetics; and(2)recommended public health information strategies to reduce potentially unsafe exposures from cosmetics.(c)Authorization of appropriationsTo carry out this section, there is authorized to be appropriated $7,500,000, for the period of fiscal years beginning with the fiscal year including the date of enactment of this section and running through the fifth fiscal year commencing after such date of enactment. .4.Research on health concerns impacting professional nail, hair, and beauty salon workersPart P of title III of the Public Health Service Act (42 U.S.C. 280 et seq.), as amended by section 4, is further amended by adding at the end the following:399V–8.Research on health concerns impacting professional nail, hair, and beauty salon workers(a)In generalThe Secretary shall—(1)conduct, or award grants for, research relating to basic, epidemiological, and social scientific investigations into—(A)the chemicals that are linked to adverse health effects and most commonly found in cosmetics used by professional nail, hair, and beauty salon workers;(B)the types and categories of professional salon products containing such chemicals and the availability of safer alternatives; or(C)the specific adverse health effects experienced by professional nail, hair, and beauty salon workers from exposure to unsafe chemicals present in cosmetics used in nail, hair, and beauty salons; and(2)disseminate the results of the investigations conducted or supported under paragraph (1) to help professional nail, hair, and beauty salon workers identify and eliminate potentially unsafe chemical exposures in their workplace.(b)ReportNot later than 5 years after awarding the first grant under this section, the Secretary shall make publicly available and submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report on the results of the investigations conducted or supported under subsection (a), including—(1)summary findings, with respect to professional nail, hair, and beauty salon workers, on—(A)chemicals of concern and products and product categories containing ingredients linked to adverse health effects; and(B)the demographics of the populations using these products and product categories; and(2)recommended occupational health information strategies for professional nail, hair, and beauty salon workers to reduce potentially unsafe exposures to cosmetics.(c)DefinitionsIn this section:(1)The term ingredient means an intentionally added chemical in a cosmetic that has a technical or functional effect, including—(A)the breakdown products of an intentionally added chemical that also have a functional or technical effect in the cosmetic;(B)a fragrance, flavor, preservative, or colorant (and the components thereof); and(C)any individual component that the Secretary deems an ingredient for purposes of this section.(1)The term salon worker means a cosmetologist, nail technician, barber, or esthetician who applies or administers a cosmetic within the scope of their business practices.(d)Authorization of appropriationsTo carry out this section, there is authorized to be appropriated $7,500,000, for the period of fiscal years beginning with the fiscal year including the date of enactment of this section and running through the fifth fiscal year commencing after such date of enactment. .5.Support for creating safer alternatives(a)In generalThe Secretary of Health and Human Services (in this section referred to as the Secretary), acting through the Commissioner of Food and Drugs, in consultation with the Administrator of the Environmental Protection Agency, shall award grants to support research focused on the design of cosmetic chemicals that have no inherent toxicity or association with adverse health effects.(b)PriorityIn awarding grants under subsection (a), the Secretary shall give priority to applicants proposing to focus on—(1)replacing chemicals in professional cosmetic products used by professional nail, hair, and beauty salon workers with chemicals that are not associated with adverse health events;(2)replacing chemicals in cosmetic products marketed to women and girls of color, including any such beauty, personal hygiene, and intimate care products, with chemicals that are not associated with adverse health events; or(3)providing assistance in creating safer product formulations to minority-owned cosmetic companies that are manufacturing and marketing cosmetic products to women or girls of color or professional nail, hair, and beauty salon workers.(c)DefinitionIn this section, the term salon worker means a cosmetologist, nail technician, barber, or esthetician who applies or administers a cosmetic within the scope of their business practices.(d)Authorization of appropriationsTo carry out this section, there is authorized to be appropriated $10,000,000 for the period of fiscal years beginning with the fiscal year including the date of enactment of this section and running through the fifth fiscal year commencing after such date of enactment.6.Professional salon product ingredient disclosure in labeling and on websites(a)In generalChapter VI of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 361 et seq.) is amended by adding at the end the following:604.Professional salon product ingredient disclosure in labeling and on websites(a)In generalThe Secretary shall require that—(1)the label on each package of cosmetics for professional use bears a declaration of the name of each ingredient in such cosmetic in descending order of predominance; and(2)the internet website of any company manufacturing, distributing, or selling cosmetics for professional use bears a declaration of the name of each ingredient in each such cosmetic in descending order of predominance.(b)Adjustments for label size(1)Rules for small productsNot later than 6 months after the date of the enactment of this section, the Secretary shall issue regulations that apply to any cosmetic for which the packaging is not of sufficient size to bear a label that meets the requirements of subsection (a). (2)Requirements for disclosing to customers and clientsThe regulations under paragraph (1) shall establish requirements for listing ingredients on the label of such cosmetics and additional requirements, as appropriate.(c)DefinitionIn this section:(1)IngredientThe term ingredient means an intentionally added chemical in a cosmetic that has a technical or functional effect, including—(A)the breakdown products of an intentionally added chemical that also have a functional or technical effect in the cosmetic;(B)a fragrance, flavor, preservative, or colorant (and the components thereof); and(C)any individual component that the Secretary deems an ingredient for purposes of this section.(2)Professional useThe term professional use means—(A)the application of a cosmetic to a human customer or client that is intended only for use by an employee or contractor, in settings such as cosmetology, nail care, barbering, esthetics, spa, and other professions as determined by the Secretary through regulation; or(B)the use by, or application to a human of a cosmetic purchased from a hair salon, nail salon, beauty salon, spa, or other establishment that provides cosmetic treatment services for humans..(b)MisbrandingSection 602 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 362) is amended by adding at the end the following:(g)If it is not labeled as required under section 604(a)(1)..(c)Prohibited actSection 301 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 331) is amended by adding at the end the following:(fff)The failure to post a declaration on the internet website of any company manufacturing, distributing, or selling cosmetics for professional use as required under section 604(a)(2)..(d)ApplicabilitySections 604, 602(g), and 301(fff) of the Federal Food, Drug, and Cosmetic Act, as added by this section, shall apply beginning on a date that is determined by the Commissioner of Food and Drugs, but is not later than 18 months after the date of enactment of this Act. 7.Translation of and access to safety data sheets(a)In generalNot later than 18 months after the date of enactment of this Act, the Secretary of Labor shall issue a standard under section 6 of the Occupational Safety and Health Act of 1970 (29 U.S.C. 655) that requires the following:(1)Each manufacturer or importer selling any cosmetic for professional use shall—(A)obtain or develop a safety data sheet described in subsection (b) for each such cosmetic or personal care product that—(i)the manufacturer or importer produces or imports; and(ii)includes a hazardous chemical, or a product ingredient associated with any chemical hazard, that is classified as a health hazard in accordance with the criteria found in section 1910.1200(d) of title 29 of the Code of Federal Regulations, and any successor regulations; and(B)make the safety data sheet available on the manufacturer or importer’s website (in addition to any other required manner of making such sheet available) to distributors and employers, including owners of hair, nail, and beauty salons or spas or other establishments that provide cosmetic services for humans, in English, Spanish, Vietnamese, Chinese, Korean, and upon request other languages.(2)Each distributor of a cosmetic or personal care product for professional use shall distribute and provide safety data sheets described in subsection (b) in the same manner as a distributor of a chemical hazard is required to distribute and provide safety data sheets under section 1910.1200(g) of title 29, Code of Federal Regulations, or any successor regulations.(3)Each employer, including any operator of a salon or other establishment described in paragraph (1)(B), shall—(A)have a safety data sheet in the workplace for each cosmetic or personal care product for professional use that is used in the course of the employer’s business;(B)make such safety data sheet available to all employees of the employer who are exposed or use the product to the same extent and in the same manner as safety data sheets are required to be made available under section 1910.1200(g) of title 29, Code of Federal Regulations, or any successor regulations; and(C)upon request, provide employees with translations of such safety data sheet in other languages, including Spanish, Vietnamese, Chinese, Korean, and upon request other languages.(b)Contents of safety data sheetA safety data sheet for a cosmetic or personal care product for professional use described in this section shall—(1)contain the information required in a safety data sheet under section 1910.1200(g) of title 29, Code of Federal Regulations, or any successor regulations, for each hazardous chemical, or product ingredient associated with any chemical hazard, described in subsection (a)(1)(A)(ii); and(2)include the following statement: This safety data sheet is also available in multiple languages by contacting the manufacturer, using the contact information provided on this sheet..(c)DefinitionsIn this section:(1)IngredientThe term ingredient means an intentionally added chemical in a cosmetic that has a technical or functional effect, including—(A)the breakdown products of an intentionally added chemical that also have a functional or technical effect in the cosmetic;(B)a fragrance, flavor, preservative, or colorant (and the components thereof); and(C)any individual component that the Secretary deems an ingredient for purposes of this section.(2)ManufacturerThe term manufacturer means the entity that produces ingredients or combines one or more ingredients to produce a cosmetic product.(3)Professional use definedThe term professional use has the meaning given to such term in section 604 of the Federal Food, Drug, and Cosmetic Act, as added by section 6.8.Interagency Council on Cosmetic Safety(a)In generalThe Secretary of Health and Human Services shall establish and maintain an Interagency Council on Cosmetic Safety for the purpose of sharing data and promoting collaboration on cosmetic safety and generating solutions to address the adverse health effects experienced by women and girls of color and professional nail, hair, and beauty salon workers because of using or working with unsafe chemicals in cosmetics and personal care products.(b)CompositionThe members of the Interagency Council shall consist of the following:(1)The Commissioner of Food and Drugs (or the Commissioner’s designee).(2)The Director of the National Institute of Environmental Health Sciences (or the Director’s designee).(3)The Director of the Centers for Disease Control and Prevention (or the Director’s designee).(4)The Assistant Secretary of Labor for Occupational Safety and Health (or the Assistant Secretary’s designee).(5)The Administrator of the Environmental Protection Agency (or the Administrator’s designee).(6)The Administrator of the Small Business Administration (or the Administrator’s designee).(7)The Secretary of Labor (or the Secretary’s designee).(c)Use of data from Federal sourcesFor purposes of this section, the Secretary, as appropriate, shall request and utilize ingredient and cosmetic toxicity, use, and exposure data from other Federal agencies.(d)ReportNot later than 1 year after the date of enactment of this Act, the Secretary shall make publicly available and submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report including—(1)a summary of data shared with the Interagency Council by other Federal agencies;(2)a listing and description of the Secretary’s use of ingredient, toxicity, and exposure data from other Federal agencies that was found to be relevant to cosmetic use; and(3)recommended research, occupational health, small business assistance, public information, and other strategies to reduce potentially unsafe exposures to cosmetic chemicals.(e)DefinitionsIn this section:(1)The term ingredient means an intentionally added chemical in a cosmetic that has a technical or functional effect, including—(A)the breakdown products of an intentionally added chemical that also have a functional or technical effect in the cosmetic;(B)a fragrance, flavor, preservative, or colorant (and the components thereof); and(C)any individual component that the Secretary deems an ingredient for purposes of section.(2)The term Interagency Council means the Interagency Council on Cosmetic Safety.(3)The term salon worker means a cosmetologist, nail technician, barber, or esthetician who applies or administers a cosmetic within the scope of their business practices.(4)The term Secretary means the Secretary of Health and Human Services.9.Inclusion of communities of color in ingredient reviewChapter VI of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 361 et seq.), as amended by section 6, is further amended by adding at the end the following: 605.Inclusion of communities of color in ingredient review(a)In generalThe Secretary shall establish and implement a process to evaluate cosmetics (including nonfunctional constituents and ingredients) marketed to and used by women and girls of color to ensure that such cosmetics are in full compliance with the requirements of this chapter.(b)Process requirementsThis process established under subsection (a) shall include—(1)issuing guidance on the process;(2)selecting cosmetics, nonfunctional constituents, and ingredients for evaluation under such process, including those linked to adverse health effects in women and girls of color;(3)review of the relevant scientific evidence, clinical studies, data, or other information; and(4)convening a public meeting with respect to each cosmetic, nonfunctional constituent, and ingredient that is selected for evaluation.(c)Advisory committee(1)In generalThe Secretary shall maintain a permanent advisory committee to advise the Secretary in connection with the process under this section.(2)MembershipThe members of such advisory committee shall include—(A)the Deputy Assistant Secretary for Minority Health (or the Deputy Assistant Secretary’s designee); and(B)individuals from nonprofit organizations representing women of color and professional nail, hair, and beauty salon workers.(d)DefinitionsIn this section:(1)The term ingredient has the meaning given to such term in section 604. (2)The term nonfunctional constituent means a chemical that has no functional or technical effect on the product or ingredient and is present—(A)as an incidental component of an intentionally added ingredient;(B)as a breakdown product of an intentionally added ingredient;(C)as a byproduct of the manufacturing process;(D)due to the storage of primary substances; or(E)due to the instability of the packaging.(3)The term salon worker means a cosmetologist, nail technician, barber, or esthetician who applies or administers a cosmetic within the scope of their business practices..


114 HR 2872 IH: Opioid Addiction Treatment Modernization Act
U.S. House of Representatives
2015-06-24
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

I
114th CONGRESS
1st Session
H. R. 2872
IN THE HOUSE OF REPRESENTATIVES

June 24, 2015
Mr. Bucshon (for himself and Mr. Womack) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned

A BILL
To amend the Controlled Substances Act to modernize the treatment of opioid addiction, and for other purposes.

1.Short titleThis Act may be cited as the Opioid Addiction Treatment Modernization Act. 2.FindingsThe Congress finds that opioid addiction has become a public health epidemic that must be addressed by increasing awareness and access to all treatment options for opioid addiction, overdose reversal, and relapse prevention.
3.Opioid addiction treatment modernization
(a)In generalSection 303(g) of the Controlled Substances Act (21 U.S.C. 823(g)) is amended— (1)by adding at the end the following:

(3)The standards under paragraph (1)(A) (for determining whether a practitioner is qualified to engage in the treatment with respect to which registration is sought) shall include a requirement for completion, every 2 years, of training— (A)provided (through classroom situations, seminars at professional society meetings, electronic communications, or otherwise) by an organization such as the American Society of Addiction Medicine, the American Academy of Addiction Psychiatry, the American Medical Association, the American Osteopathic Association, the American Psychiatric Association, the American Association for the Treatment of Opioid Dependence, the National Council for Behavioral Health, or any other organization that the Secretary determines is appropriate; and
(B)addressing— (i)opioid detoxification;
(ii)appropriate clinical use of all drugs approved by the Food and Drug Administration for the treatment of opioid addiction; (iii)the need for initial and periodic assessments of each patient;
(iv)the development of an individualized treatment plan for each patient; and (v)the importance of providing overdose reversal and relapse prevention, and appropriate counseling and other services.;
(2)in paragraph (2)(B), by inserting and annually thereafter, after before the initial dispensing of narcotic drugs in schedule III, IV, or V or combinations of such drugs to patients for maintenance or detoxification treatment,; (3)by amending paragraph (2)(B)(ii) to read as follows:

(ii)With respect to patients to whom the practitioner will provide such drugs or combinations of drugs, the practitioner has the capacity to provide directly or by referral— (I)all drugs approved by the Food and Drug Administration for the treatment of opioid addiction, including, as available, opioid maintenance, detoxification, and overdose reversal and relapse prevention; and
(II)appropriate counseling and ancillary services.; (4)by redesignating clause (iii) of paragraph (2)(B) as clause (iv);
(5)after paragraph (2)(B)(ii), by inserting the following:   (iii)The practitioner maintains a diversion control plan that contains specific measures to reduce the likelihood of the diversion of controlled substances prescribed by the practitioner for the treatment of opioid addiction.;
(6)by amending paragraph (2)(G)(ii) to read as follows:   (ii)The term qualifying physician means a physician who meets the following:
(I)The physician is licensed under State law. (II)The physician meets one or more of the following conditions:
(aa)The physician holds a subspecialty board certification in addiction psychiatry from the American Board of Medical Specialties. (bb)The physician holds an addiction certification from the American Society of Addiction Medicine.
(cc)The physician holds a subspecialty board certification in addiction medicine from the American Osteopathic Association. (dd)The physician has participated as an investigator in one or more clinical trials leading to the approval of a narcotic drug in schedule III, IV, or V for maintenance or detoxification treatment or the approval of a drug for the treatment of opioid addiction, as demonstrated by a statement submitted to the Secretary by the sponsor of such approved drug.
(ee)The physician has such other training or experience as the State medical licensing board (of the State in which the physician will provide maintenance or detoxification treatment) considers to demonstrate the ability of the physician to treat and manage opiate-dependent patients. (ff)The physician has such other training or experience as the Secretary considers to demonstrate the ability of the physician to treat and manage opiate-dependent patients. Any criteria of the Secretary under this item shall be established by regulation. Any such criteria are effective only for 3 years after the date on which the criteria are promulgated, but may be extended for such additional discrete 3-year periods as the Secretary considers appropriate for purposes of this item. Such an extension of criteria may only be effectuated through a statement published in the Federal Register by the Secretary during the 30-day period preceding the end of the 3-year period involved.
(iii)The physician completes, with respect to the treatment and management of opiate-dependent patients, not less than 8 hours of training described in paragraph (3) not less frequently than every 2 years. (iv)The physician obtains in writing from each patient a signed acknowledgment that the patient—
(I)will be subject to medication adherence and substance use monitoring; (II)understands available treatment options, including drugs approved by the Food and Drug Administration for the treatment of opioid addiction and their potential risks and benefits; and
(III)has an individualized treatment plan.; and (7)by amending paragraph (2)(H)(ii) to read as follows:

(ii)Not later than one year after the date of enactment of the Opioid Addiction Treatment Modernization Act, the Secretary shall update the treatment improvement protocol containing best practice guidelines for the treatment of opiate-dependent patients. The Secretary shall update such protocol in consultation with the Director of the National Institute on Drug Abuse, the Administrator of the Drug Enforcement Administration, the Commissioner of Food and Drugs, the Administrator of the Substance Abuse and Mental Health Services Administration, and other substance abuse disorder professionals. Updates to the protocol shall be guided by science. . (b)Inspection authorityThe Secretary of Health and Human Services or the Attorney General of the United States may inspect persons that are registered under section 303(g) of the Controlled Substances Act (21 U.S.C. 823(g)) to ensure compliance with the requirements in this Act (and the amendments made by this Act) with respect to which noncompliance may result in a revocation or suspension of the practitioner’s registration.
(c)Certification of complianceNot later than 1 year after the date of enactment of this Act, all practitioners who, as of such date of enactment, are permitted to dispense narcotic drugs to individuals (for maintenance treatment or detoxification treatment) pursuant to paragraph (1) or (2) of section 303(g) of the Controlled Substances Act (21 U.S.C. 823(g)) shall submit a certification to the Secretary of Health and Human Services of compliance with the provisions of such section 303(g), as amended by this Act. (d)Reports to Congress (1)In generalNot later than 1 year after the date of enactment of this Act, and every 5 years thereafter, the Comptroller General of the United States shall—
(A)perform a thorough review of the provision of opioid addiction treatment services in the United States; and (B)submit a report to the Congress on the findings and conclusions of such review.
(2)ContentsEach report under paragraph (1) shall include— (A)an assessment of compliance with the requirements of section 303(g) of the Controlled Substances Act, as amended by this Act;
(B)a description of the measures taken by the Secretary of Health and Human Services to ensure such compliance; and (C)an assessment of—
(i)whether the full range of science- and evidence-based treatment options for opioid addiction are fully integrated into treatment; and (ii)the circumstances surrounding medication diversion and misuse.


		II
		111th CONGRESS
		1st Session
		S. 621
		IN THE SENATE OF THE UNITED STATES

			March 17, 2009
			Mr. Durbin (for himself
			 and Mr. Cochran) introduced the following
			 bill; which was read twice and referred to the
			 Committee on Health, Education, Labor,
			 and Pensions

		A BILL
		To amend the Public Health Service Act to coordinate
		  Federal congenital heart disease research efforts and to improve public
		  education and awareness of congenital heart disease, and for other
		  purposes.

		1.Short
			 titleThis Act may be cited as
			 the Congenital Heart Futures
			 Act.
		2.FindingsCongress finds the following:
			(1)Congenital heart
			 defects are the most common and most deadly group of birth defects and affect
			 nearly 1 percent of all live births, approximately 36,000 births a year. A
			 child is born with a congenital heart defect every 15 minutes.
			(2)Congenital heart
			 disease is a rapidly growing national health problem. Childhood survival has
			 risen from below 20 percent in 1950 to more than 90 percent today. Due to the
			 increase in childhood survival, the congenital heart disease population
			 increases by an estimated 5 percent every year.
			(3)Approximately
			 800,000 children and 1,000,000 adults in the United States are now living with
			 congenital heart disease and require highly specialized life-long cardiac
			 care.
			(4)There is no cure
			 for congenital heart disease. Even survivors of successful childhood treatment
			 can face life-long risks from congenital heart disease, including heart
			 failure, rhythmic disorders, stroke, renal dysfunction, and neurocognitive
			 dysfunction.
			(5)Less than 10
			 percent of adults living with complex congenital heart disease currently
			 receive recommended cardiac care. Many individuals with congenital heart
			 disease are unaware that they require life-long specialized health
			 surveillance. Delays in care can result in premature death and
			 disability.
			(6)The estimated
			 life expectancy for those with congenital heart disease is significantly lower
			 than for the general population. The life expectancy for those born with
			 moderately complex heart defects is 55, while the estimated life expectancy for
			 those born with highly complex defects is between 35 and 40.
			(7)Despite the
			 prevalence and seriousness of the disease, Federal research, data collection,
			 education, and awareness activities are limited.
			(8)The strategic
			 plan of the National Heart, Lung, and Blood Institute completed in 2007 notes
			 that successes over several decades have enabled people with congenital
			 heart diseases to live beyond childhood, but too often inadequate data are
			 available to guide their treatment as adults.
			(9)The strategic
			 plan for the Division of Cardiovascular Diseases at the National Heart, Lung
			 and Blood Institute, completed in 2008, set goals for congenital heart disease
			 research, including understanding the development and genetic basis of
			 congenital heart disease, improving evidence-based care and treatment of
			 children with congenital and acquired pediatric heart disease, and improving
			 evidence-based care and treatment of adults with congenital heart
			 disease.
			3.Public education
			 and awareness of congenital heart diseaseTitle III of the Public Health Service Act
			 (42 U.S.C. 241 et seq.) is amended by adding at the end the following:

				SPrograms relating
				to congenital heart disease
					399HH.Public
				education and awareness of congenital heart disease
						(a)In
				generalThe Secretary, acting
				through the Director of the Centers for Disease Control and Prevention and in
				collaboration with appropriate congenital heart disease patient organizations
				and professional organizations, may directly or through grants, cooperative
				agreements, or contracts to eligible entities conduct, support, and promote a
				comprehensive public education and awareness campaign to increase public and
				medical community awareness regarding congenital heart disease, including the
				need for life-long treatment of congenital heart disease survivors.
						(b)Eligibility for
				grantsTo be eligible to
				receive a grant, cooperative agreement, or contract under this section, an
				entity shall be a State or private nonprofit entity and shall submit to the
				Secretary an application at such time, in such manner, and containing such
				information as the Secretary may
				require.
						.
		4.National
			 congenital heart disease registryTitle III of the Public Health Service Act
			 (42 U.S.C. 241 et seq.), as amended by section 3, is further amended by adding
			 at the end the following:

				399II.National
				congenital heart disease registry
					(a)In
				generalThe Secretary, acting
				through the Director of the Centers for Disease Control and Prevention,
				may—
						(1)enhance and expand infrastructure to track
				the epidemiology of congenital heart disease and to organize such information
				into a comprehensive, nationwide registry of actual occurrences of congenital
				heart disease, to be known as the National Congenital Heart Disease
				Registry; or
						(2)award a grant to one eligible entity to
				undertake the activities described in paragraph (1).
						(b)PurposeThe
				purpose of the Congenital Heart Disease Registry shall be to facilitate further
				research into the types of health services patients use and to identify
				possible areas for educational outreach and prevention in accordance with
				standard practices of the Centers for Disease Control and Prevention.
					(c)ContentThe
				Congenital Heart Disease Registry—
						(1)may include
				information concerning the incidence and prevalence of congenital heart disease
				in the United States;
						(2)may be used to
				collect and store data on congenital heart disease, including data
				concerning—
							(A)demographic
				factors associated with congenital heart disease, such as age, race, ethnicity,
				sex, and family history of individuals who are diagnosed with the
				disease;
							(B)risk factors
				associated with the disease;
							(C)causation of the
				disease;
							(D)treatment
				approaches; and
							(E)outcome measures,
				such that analysis of the outcome measures will allow derivation of
				evidence-based best practices and guidelines for congenital heart disease
				patients; and
							(3)may ensure the
				collection and analysis of longitudinal data related to individuals of all ages
				with congenital heart disease, including infants, young children, adolescents,
				and adults of all ages, including the elderly.
						(d)Coordination
				with Federal, State, and local registriesIn establishing the
				National Congenital Heart Registry, the Secretary may identify, build upon,
				expand, and coordinate among existing data and surveillance systems, surveys,
				registries, and other Federal public health infrastructure, including—
						(1)State birth
				defects surveillance systems;
						(2)the State birth
				defects tracking systems of the Centers for Disease Control and
				Prevention;
						(3)the Metropolitan
				Atlanta Congenital Defects Program; and
						(4)the National
				Birth Defects Prevention Network.
						(e)Public
				accessThe Congenital Heart Disease Registry shall be made
				available to the public, including congenital heart disease researchers.
					(f)Patient
				privacyThe Secretary shall ensure that the Congenital Heart
				Disease Registry is maintained in a manner that complies with the regulations
				promulgated under section 264 of the Health Insurance Portability and
				Accountability Act of 1996.
					(g)Eligibility for
				grantTo be eligible to
				receive a grant under subsection (a)(2), an entity shall—
						(1)be a public or private nonprofit entity
				with specialized experience in congenital heart disease; and
						(2)submit to the Secretary an application at
				such time, in such manner, and containing such information as the Secretary may
				require.
						.
		5.Advisory
			 committee on congenital heart diseaseTitle III of the Public Health Service Act
			 (42 U.S.C. 241 et seq.), as amended by section 4, is further amended by adding
			 at the end the following:

				399JJ.Advisory
				committee on congenital heart disease
					(a)EstablishmentThe Secretary, acting through the Director
				of the Centers for Disease Control and Prevention, may establish an advisory
				committee, to be known as the Advisory Committee on Congenital Heart
				Disease (referred to in this section as the Advisory
				Committee).
					(b)MembershipThe members of the Advisory Committee may
				be appointed by the Secretary, acting through the Centers for Disease Control
				and Prevention, and shall include—
						(1)at least one representative from—
							(A)the National Institutes of Health;
							(B)the Centers for
				Disease Control and Prevention; and
							(C)a national patient advocacy organization
				with experience advocating on behalf of patients living with congenital heart
				disease;
							(2)at least one epidemiologist who has
				experience working with data registries;
						(3)clinicians,
				including—
							(A)at least one with experience diagnosing or
				treating congenital heart disease; and
							(B)at least one with
				experience using medical data registries; and
							(4)at least one
				publicly or privately funded researcher with experience researching congenital
				heart disease.
						(c)DutiesThe
				Advisory Committee may review information and make recommendations to the
				Secretary concerning—
						(1)the development
				and maintenance of the National Congenital Heart Disease Registry established
				under section 399II;
						(2)the type of data
				to be collected and stored in the National Congenital Heart Disease
				Registry;
						(3)the manner in
				which such data is to be collected;
						(4)the use and
				availability of such data, including guidelines for such use; and
						(5)other matters, as
				the Secretary determines to be appropriate.
						(d)ReportNot
				later than 180 days after the date on which the Advisory Committee is
				established and annually thereafter, the Advisory Committee shall submit a
				report to the Secretary concerning the information described in subsection (c),
				including recommendations with respect to the results of the Advisory
				Committee's review of such
				information.
					.
		6.Congenital heart
			 disease researchSubpart 2 of
			 part C of title IV of the Public Health Service Act (42 U.S.C. 285b et seq.) is
			 amended by adding at the end the following:

				425.Congenital
				heart disease
					(a)In
				generalThe Director of the Institute may expand, intensify, and
				coordinate research and related activities of the Institute with respect to
				congenital heart disease, which may include congenital heart disease research
				with respect to—
						(1)causation of
				congenital heart disease, including genetic causes;
						(2)long-term
				outcomes in individuals with congenital heart disease, including infants,
				children, teenagers, adults, and elderly individuals;
						(3)diagnosis,
				treatment, and prevention;
						(4)studies using
				longitudinal data and retrospective analysis to identify effective treatments
				and outcomes for individuals with congenital heart disease; and
						(5)identifying
				barriers to life-long care for individuals with congenital heart
				disease.
						(b)Coordination of
				research activitiesThe Director of the Institute may coordinate
				research efforts related to congenital heart disease among multiple research
				institutions and may develop research networks.
					(c)Minority and
				medically underserved communitiesIn carrying out the activities
				described in this section, the Director of the Institute shall consider the
				application of such research and other activities to minority and medically
				underserved
				communities.
					.
		7.Authorization of
			 appropriationsThere are
			 authorized to be appropriated to carry out the amendments made by this Act such
			 sums as may be necessary for each of fiscal years 2010 through 2014.


117 S1905 IS: Freedom To Fly Act
U.S. Senate
2021-05-27
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

II117th CONGRESS1st SessionS. 1905IN THE SENATE OF THE UNITED STATESMay 27, 2021Mr. Scott of Florida introduced the following bill; which was read twice and referred to the Committee on Commerce, Science, and TransportationA BILLTo prohibit the Transportation Security Administration from asking passengers on domestic flights for information regarding vaccinations.1.Short titleThis Act may be cited as the Freedom To Fly Act.2.Prohibition on requesting vaccination information from passengers on domestic flights(a)In generalThe Secretary of Homeland Security and the Administrator of the Transportation Security Administration may not prescribe or implement any regulation or policy that would allow employees of the Transportation Security Administration to request information relating to vaccinations from any passenger traveling on a flight between States or territories or possessions of the United States.(b)Rule of constructionSubsection (a) does not limit the authority of the Director of the Centers for Disease Control and Prevention to issue guidance or prescribe regulations relating to public health.


109 HR 297 IH: To restore the prohibition on the commercial sale and slaughter of wild free-roaming horses and burros.
U.S. House of Representatives
2005-01-25
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

I
109th CONGRESS
1st Session
H. R. 297
IN THE HOUSE OF REPRESENTATIVES

January 25, 2005
Mr. Rahall (for himself and Mr. Whitfield) introduced the following bill; which was referred to the Committee on Resources

A BILL
To restore the prohibition on the commercial sale and slaughter of wild free-roaming horses and burros.

1.Sale of wild free-roaming horses and burros
(a)In GeneralSection 3(d)(5) of Public Law 92–195 (16 U.S.C. 1333(d)(5)) is amended—
(1)by striking the period and inserting the following: Provided, That no wild free-roaming horse or burro or its remains may be sold or transferred for consideration for processing into commercial products.; and
(2)by striking subsection (e).
(b)Criminal provisionsSection (8)(a)(4) of Public Law 92–195 (16 U.S.C. 1338(a)(4)) is amended by striking except as provided in section 3(e),.


115 HR 7013 IH: Phoenix VA Congressional Oversight Act
U.S. House of Representatives
2018-10-02
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

I115th CONGRESS2d SessionH. R. 7013IN THE HOUSE OF REPRESENTATIVESOctober 2, 2018Mr. Biggs introduced the following bill; which was referred to the Committee on Veterans' AffairsA BILLTo direct the Secretary of Veterans Affairs to carry out a pilot program to improve the ability of Members of Congress to assist constituents with respect to benefits for veterans.
1.Short titleThis Act may be cited as the Phoenix VA Congressional Oversight Act. 2.Pilot program to improve constituent services (a)Pilot programThe Secretary of Veterans Affairs shall carry out a pilot program to improve the ability of Members of Congress to assist constituents pursuant to subsections (b) and (c).
(b)Congressional Relations TeamIn carrying out the pilot program under subsection (a), the Secretary shall establish a dedicated congressional relations team at the location specified in subsection (d). Such team shall consist of employees of the Department of Veterans Affairs whose only duties relate to assisting Members and committees of Congress with respect to casework issues at each health care system of the Department in such location. (c)Use of spaceUpon request of any Member of Congress from the State of the location specified in subsection (d), the Secretary shall authorize the Member to use a facility of the Department at such location for the purposes of meeting with constituents of the Member.
(d)LocationThe Secretary shall carry out the pilot program in Arizona, including at the Phoenix health care system of the Department. (e)ReportNot later than two years after the date of the enactment of this Act, the Secretary shall submit to the Committees on Veterans’ Affairs of the House of Representatives and the Senate a report on the pilot program under subsection (a), including whether the Secretary recommends expanding such pilot program.


114 HRES 29 EH: Electing Members to certain standing committees of the House of Representatives.
U.S. House of Representatives
2015-01-13
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

IV
114th CONGRESS
1st Session
H. RES. 29
In the House of Representatives, U. S.,

January 13, 2015

RESOLUTION
Electing Members to certain standing committees of the House of Representatives.

That the following named Members be, and are hereby, elected to the following standing committees of the House of Representatives:  Committee on Agriculture:Mr. Goodlatte; Mr. Lucas; Mr. King of Iowa; Mr. Neugebauer; Mr. Rogers of Alabama; Mr. Thompson of Pennsylvania; Mr. Gibbs; Mr. Austin Scott of Georgia; Mr. Crawford; Mr. DesJarlais; Mr. Gibson; Mrs. Hartzler; Mr. Benishek; Mr. Denham; Mr. LaMalfa; Mr. Rodney Davis of Illinois; Mr. Yoho; Mrs. Walorski; Mr. Allen; Mr. Mike Bost of Illinois; Mr. Rouzer; Mr. Abraham; Mr. Emmer of Minnesota; Mr. Moolenaar; and Mr. Newhouse.

Committee on Appropriations:Mr. Frelinghuysen; Mr. Aderholt; Ms. Granger; Mr. Simpson; Mr. Culberson; Mr. Crenshaw; Mr. Carter of Texas; Mr. Calvert; Mr. Cole; Mr. Diaz-Balart; Mr. Dent; Mr. Graves of Georgia; Mr. Yoder; Mr. Womack; Mr. Fortenberry; Mr. Rooney of Florida; Mr. Fleischmann; Ms. Herrera Beutler; Mr. Joyce; Mr. Valadao; Mr. Harris; Mrs. Roby; Mr. Amodei; Mr. Stewart; Mr. Rigell; Mr. Jolly; Mr. Young of Iowa; and Mr. Jenkins of West Virginia. Committee on Armed Services:Mr. Jones; Mr. Forbes; Mr. Miller of Florida; Mr. Wilson of South Carolina; Mr. LoBiondo; Mr. Bishop of Utah; Mr. Turner; Mr. Kline; Mr. Rogers of Alabama; Mr. Franks of Arizona; Mr. Shuster; Mr. Conaway; Mr. Lamborn; Mr. Wittman; Mr. Hunter; Mr. Fleming; Mr. Coffman; Mr. Gibson; Mrs. Hartzler; Mr. Heck of Nevada; Mr. Austin Scott of Georgia; Mr. Palazzo; Mr. Brooks of Alabama; Mr. Nugent; Mr. Cook; Mr. Bridenstine; Mr. Wenstrup; Mrs. Walorski; Mr. Byrne; Mr. Graves of Missouri; Mr. Zinke; Ms. Stefanik; Ms. McSally; Mr. Knight; and Mr. MacArthur.

Committee on Education and the Workforce:Mr. Wilson of South Carolina; Ms. Foxx; Mr. Hunter; Mr. Roe of Tennessee; Mr. Thompson of Pennsylvania; Mr. Walberg; Mr. Salmon; Mr. Guthrie; Mr. Rokita; Mr. Barletta; Mr. Heck of Nevada; Mr. Messer; Mr. Byrne; Mr. Brat; Mr. Carter of Georgia; Mr. Bishop of Michigan; Mr. Grothman; Mr. Russell; Mr. Curbelo of Florida; Ms. Stefanik; and Mr. Allen. Committee on Energy and Commerce:Mr. Barton; Mr. Whitfield; Mr. Shimkus; Mr. Pitts; Mr. Walden; Mr. Murphy of Pennsylvania; Mr. Burgess; Mrs. Blackburn; Mr. Scalise; Mr. Latta; Mrs. McMorris Rodgers; Mr. Harper; Mr. Lance; Mr. Guthrie; Mr. Olson; Mr. McKinley; Mr. Pompeo; Mr. Kinzinger of Illinois; Mr. Griffith; Mr. Bilirakis; Mr. Johnson of Ohio; Mr. Long; Mrs. Ellmers of North Carolina; Mr. Bucshon; Mr. Flores; Mrs. Brooks of Indiana; Mr. Mullin; Mr. Hudson; Mr. Collins of New York; and Mr. Cramer.

Committee on Financial Services: Mr. King of New York; Mr. Royce; Mr. Lucas; Mr. Garrett; Mr. Neugebauer; Mr. McHenry; Mr. Pearce; Mr. Posey; Mr. Fitzpatrick; Mr. Westmoreland; Mr. Luetkemeyer; Mr. Huizenga of Michigan; Mr. Duffy; Mr. Hurt of Virginia; Mr. Stivers; Mr. Fincher; Mr. Stutzman; Mr. Mulvaney; Mr. Hultgren; Mr. Ross; Mr. Pittenger; Mrs. Wagner; Mr. Barr; Mr. Rothfus; Mr. Messer; Mr. Schweikert; Mr. Dold; Mr. Guinta; Mr. Tipton; Mr. Williams; Mr. Poliquin; Mrs. Love; and Mr. Hill. Committee on Foreign Affairs:Mr. Smith of New Jersey; Ms. Ros-Lehtinen; Mr. Rohrabacher; Mr. Chabot; Mr. Wilson of South Carolina; Mr. McCaul; Mr. Poe of Texas; Mr. Salmon; Mr. Issa; Mr. Marino; Mr. Duncan of South Carolina; Mr. Brooks of Alabama; Mr. Cook; Mr. Weber of Texas; Mr. Perry; Mr. DeSantis; Mr. Meadows; Mr. Yoho; Mr. Clawson of Florida; Mr. DesJarlais; Mr. Ribble; Mr. Trott; Mr. Zeldin; and Mr. Emmer of Minnesota.

Committee on Homeland Security:Mr. Smith of Texas; Mr. King of New York; Mr. Rogers of Alabama; Mrs. Miller of Michigan; Mr. Duncan of South Carolina; Mr. Marino; Mr. Palazzo; Mr. Barletta; Mr. Perry; Mr. Clawson of Florida; Mr. Katko; Mr. Hurd of Texas; Mr. Carter of Georgia; Mr. Walker; Mr. Loudermilk; Ms. McSally; and Mr. Ratcliffe.  Committee on the Judiciary:Mr. Sensenbrenner; Mr. Smith of Texas; Mr. Chabot; Mr. Issa; Mr. Forbes; Mr. King of Iowa; Mr. Franks of Arizona; Mr. Gohmert; Mr. Jordan; Mr. Poe of Texas; Mr. Chaffetz; Mr. Marino; Mr. Gowdy; Mr. Labrador; Mr. Farenthold; Mr. Collins of Georgia; Mr. DeSantis; Mrs. Mimi Walters of California; Mr. Buck; Mr. Ratcliffe; Mr. Trott; and Mr. Bishop of Michigan.

Committee on Natural Resources:Mr. Young of Alaska; Mr. Gohmert; Mr. Lamborn; Mr. Wittman; Mr. Fleming; Mr. McClintock; Mr. Thompson of Pennsylvania; Mrs. Lummis; Mr. Benishek; Mr. Duncan of South Carolina; Mr. Gosar; Mr. Labrador; Mr. LaMalfa; Mr. Byrne; Mr. Denham; Mr. Cook; Mr. Westerman; Mr. Graves of Louisiana; Mr. Newhouse; Mr. Zinke; Mr. Jody Hice of Georgia; Mrs. Radewagen; Mr. MacArthur; Mr. Mooney of West Virginia; and Mr. Hardy. Committee on Oversight and Government Reform:Mr. Mica; Mr. Turner; Mr. Duncan of Tennessee; Mr. Jordan; Mr. Walberg; Mr. Amash; Mr. Gosar; Mr. DesJarlais; Mr. Gowdy; Mr. Farenthold; Mrs. Lummis; Mr. Massie; Mr. Meadows; Mr. DeSantis; Mr. Mulvaney; Mr. Buck; Mr. Walker; Mr. Blum; Mr. Jody Hice of Georgia; Mr. Russell; Mr. Carter of Georgia; Mr. Grothman; Mr. Hurd of Texas; and Mr. Palmer.

Committee on Science, Space, and Technology:Mr. Sensenbrenner; Mr. Rohrabacher; Mr. Lucas; Mr. Neugebauer; Mr. McCaul; Mr. Palazzo; Mr. Brooks of Alabama; Mr. Hultgren; Mr. Posey; Mr. Massie; Mr. Bridenstine; Mr. Weber of Texas; Mr. Johnson of Ohio; Mr. Moolenaar; Mr. Knight; Mr. Babin; Mr. Westerman; Mrs. Comstock; Mr. Newhouse; Mr. Palmer; and Mr. Loudermilk.  Committee on Small Business:Mr. King of Iowa; Mr. Luetkemeyer; Mr. Hanna; Mr. Huelskamp; Mr. Rice of South Carolina; Mr. Gibson; Mr. Brat; Mrs. Radewagen; Mr. Knight; Mr. Hurd of Texas; Mr. Curbelo of Florida; Mr. Mike Bost of Illinois; and Mr. Hardy.

Committee on Transportation and Infrastructure:Mr. Young of Alaska; Mr. Duncan of Tennessee; Mr. Mica; Mr. LoBiondo; Mr. Graves of Missouri; Mrs. Miller of Michigan; Mr. Hunter; Mr. Crawford; Mr. Barletta; Mr. Farenthold; Mr. Gibbs; Mr. Hanna; Mr. Webster of Florida; Mr. Denham; Mr. Ribble; Mr. Massie; Mr. Rice of South Carolina; Mr. Meadows; Mr. Perry; Mr. Rodney Davis of Illinois; Mr. Sanford; Mr. Woodall; Mr. Rokita; Mr. Katko; Mr. Babin; Mr. Hardy; Mr. Costello of Pennsylvania; Mr. Graves of Louisiana; Mrs. Mimi Walters of California; Mrs. Comstock; Mr. Curbelo of Florida; Mr. Rouzer; and Mr. Zeldin. Committee on Veterans’ Affairs:Mr. Lamborn; Mr. Bilirakis; Mr. Roe of Tennessee; Mr. Benishek; Mr. Huelskamp; Mr. Coffman; Mr. Wenstrup; Mrs. Walorski; Mr. Abraham; Mr. Zeldin; Mr. Costello of Pennsylvania; Mrs. Radewagen; and Mr. Mike Bost of Illinois.

Committee on Ways and Means:Mr. Sam Johnson of Texas; Mr. Brady of Texas; Mr. Nunes; Mr. Tiberi; Mr. Reichert; Mr. Boustany; Mr. Roskam; Mr. Tom Price of Georgia; Mr. Buchanan; Mr. Smith of Nebraska; Mr. Schock; Ms. Jenkins of Kansas; Mr. Paulsen; Mr. Marchant; Mrs. Black; Mr. Reed; Mr. Young of Indiana; Mr. Kelly of Pennsylvania; Mr. Renacci; Mr. Meehan; Mrs. Noem; Mr. Holding; and Mr. Smith of Missouri.   Karen L. Haas,Clerk.


116 HRES 828 IH: Expressing the sense of the House of Representatives that the United States Trade Representative should promptly resume negotiations to conclude the Environmental Goods Agreement.
U.S. House of Representatives
2020-02-04
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

IV116th CONGRESS2d SessionH. RES. 828IN THE HOUSE OF REPRESENTATIVESFebruary 4, 2020Ms. DelBene (for herself, Mr. Panetta, Mr. Beyer, Ms. Sewell of Alabama, and Mr. Kind) submitted the following resolution; which was referred to the Committee on Ways and MeansRESOLUTIONExpressing the sense of the House of Representatives that the United States Trade Representative
			 should promptly resume negotiations to conclude the Environmental Goods
			 Agreement.

 Whereas climate change is one of the most serious threats we face today; Whereas transitioning towards a low-emissions economy must be a priority for all countries;
 Whereas, on July 8, 2014, the United States and other member countries of the World Trade Organization, accounting for nearly 90 percent of global exports in environmental goods, began negotiations on the Environmental Goods Agreement;
 Whereas the Environmental Goods Agreement would eliminate tariffs on a broad range of environmental goods including wind turbines, water treatment filters, solar water heaters, and bicycles;
 Whereas the United States is a leader in the development of environmental goods, but such goods can face tariffs as high as 50 percent when exported to other countries; and
 Whereas the negotiations represent a significant opportunity to help countries across the world access high-quality affordable environmental goods while also leveling the playing field for American manufacturers and supporting green jobs: Now, therefore, be it

 That it is the sense of the House of Representatives that not later than 90 days after the date of the adoption of this Resolution, the United States Trade Representative should resume negotiations to conclude the Environmental Goods Agreement.


115 HR 468 IH: Foreign Spill Protection Act of 2017
U.S. House of Representatives
2017-01-12
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

I115th CONGRESS1st SessionH. R. 468IN THE HOUSE OF REPRESENTATIVESJanuary 12, 2017Mr. Curbelo of Florida (for himself, Mr. Soto, Ms. Pingree, Mr. Lowenthal, Mr. Young of Alaska, Mr. Hastings, Ms. Norton, Ms. Wasserman Schultz, Mr. Gaetz, Mr. Payne, Mr. Katko, Ms. Ros-Lehtinen, Mr. Blumenauer, and Mr. Diaz-Balart) introduced the following bill; which was referred to the Committee on Transportation and InfrastructureA BILLTo amend the Oil Pollution Act of 1990 to impose penalties and provide for the recovery of removal
			 costs and damages in connection with certain discharges of oil from
			 foreign offshore units, and for other purposes.

 1.Short titleThis Act may be cited as the Foreign Spill Protection Act of 2017. 2.Liability of owners and operators of foreign facilities (a)Oil Pollution Act of 1990 amendments (1)DefinitionsSection 1001 of the Oil Pollution Act of 1990 (33 U.S.C. 2701) is amended—
 (A)in paragraph (26)(A)— (i)in clause (ii), by striking onshore or offshore facility, any person and inserting onshore facility, offshore facility, or foreign offshore unit or other facility located seaward of the exclusive economic zone, including a facility located in, on, or under any land within a foreign country, any person; and
 (ii)in clause (iii), by striking offshore facility, the person who and inserting offshore facility or foreign offshore unit or other facility located seaward of the exclusive economic zone, including a facility located in, on, or under any land within a foreign country, the person or entity that;
 (B)in paragraph (27), by inserting before the semicolon at the end the following: , including any foreign individual and any foreign public or private entity; and (C)in paragraph (32)—
 (i)by redesignating subparagraphs (D) through (F) as subparagraphs (E) through (G), respectively; (ii)by inserting after subparagraph (C) the following:

 (D)Foreign facilitiesIn the case of a foreign offshore unit or other facility located seaward of the exclusive economic zone, including a facility located in, on, or under any land within a foreign country, any person owning or operating the facility, and any leaseholder, permit holder, assignee, or holder of a right of use and easement granted under applicable foreign law for the area in which the facility is located.; and
 (iii)in subparagraph (G) (as so redesignated), by striking or offshore facility, the persons and inserting offshore facility, or foreign offshore unit or other facility located seaward of the exclusive economic zone, including a facility located in, on, or under any land within a foreign country, the persons or entities.
 (2)Actions on behalf of fundSection 1015(c) of the Oil Pollution Act of 1990 (33 U.S.C. 2715(c)) is amended, in the third sentence, by adding before the period at the end the following: , or any other facility located seaward of the exclusive economic zone, including a facility located in, on, or under any land within a foreign country.
 (b)Federal Water Pollution Control Act amendmentSection 311(a)(6) of the Federal Water Pollution Control Act (33 U.S.C. 1321(a)(6)) is amended by striking (B) and all that follows through and (C) and inserting the following (B) in the case of a facility, any person owning or operating the facility, and (C).


109 HRES 692 EH: Commending the people of the Republic of the Marshall Islands for the contributions and sacrifices they made to the United States nuclear testing program in the Marshall Islands, solemnly acknowledging the first detonation of a hydrogen bomb by the United States on March 1, 1954, on the Bikini Atoll in the Marshall Islands, and remembering that 60 years ago the United States began its nuclear testing program in the Marshall Islands.
U.S. House of Representatives
2006-04-05
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

IV
109th CONGRESS
2d Session
H. RES. 692
In the House of Representatives, U. S.,

April 5, 2006

RESOLUTION
Commending the people of the Republic of the Marshall Islands for the contributions and sacrifices they made to the United States nuclear testing program in the Marshall Islands, solemnly acknowledging the first detonation of a hydrogen bomb by the United States on March 1, 1954, on the Bikini Atoll in the Marshall Islands, and remembering that 60 years ago the United States began its nuclear testing program in the Marshall Islands.

Whereas between 1946 and 1958, the United States conducted 67 nuclear tests in the Marshall Islands, 66 of which resulted in atmospheric fallout;
Whereas the most powerful of these tests was the hydrogen weapons test codenamed Bravo, a 15-megaton device detonated on March 1, 1954, at Bikini atoll;
Whereas the Bravo detonation alone was the equivalent to 1,000 Hiroshima-sized bombs;
Whereas 17 other tests in the Marshall Islands were in the megaton range, and the total yield of the 67 tests was 108 megatons, the equivalent yield of more than 7,000 Hiroshima bombs and 93 times the total of Nevada atmospheric tests;
Whereas in July 1998, the Centers for Disease Control and Prevention estimated that 6.3 billion curies of radioactive iodine-131 were released to the atmosphere as a result of the testing in the Marshall Islands;
Whereas the 12-year nuclear testing program has been the defining experience of the modern era for the people of the Marshall Islands, and these momentous events created a common bond between the people of the Marshall Islands and the United States military and civilian personnel who shared hardships and suffering with the people of the Marshall Islands during the testing program;
Whereas as a Member State of the United Nations, the world body that once had oversight of United States stewardship of the trusteeship for the people of the Marshall Islands and their island homelands, the Republic of the Marshall Islands has an unmatched record of working in conjunction with the leadership of the United States in the pursuit of international peace and security, the rights and well-being of the peoples of the world, and in the War on Terrorism: Now, therefore, be it

That the House of Representatives—
(1)commends the people of the Republic of the Marshall Islands for the contributions and sacrifices they made to the United States nuclear testing program in the Marshall Islands;
(2)solemnly acknowledges the first detonation of a hydrogen bomb by the United States on March 1, 1954, on the Bikini Atoll in the Marshall Islands; and
(3)remembers that 60 years ago the United States began its nuclear testing program in the Marshall Islands.

Karen L. HaasClerk.


117 SRES 343 ATS: Relative to the death of the Honorable Maurice Robert Gravel, former Senator from the State of Alaska.
U.S. Senate
2021-08-07
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

III117th CONGRESS1st SessionS. RES. 343IN THE SENATE OF THE UNITED STATESAugust 7, 2021Ms. Murkowski (for herself, Mr. Sullivan, Mr. Schumer, Mr. McConnell, Ms. Baldwin, Mr. Barrasso, Mr. Bennet, Mrs. Blackburn, Mr. Blumenthal, Mr. Blunt, Mr. Booker, Mr. Boozman, Mr. Braun, Mr. Brown, Mr. Burr, Ms. Cantwell, Mrs. Capito, Mr. Cardin, Mr. Carper, Mr. Casey, Mr. Cassidy, Ms. Collins, Mr. Coons, Mr. Cornyn, Ms. Cortez Masto, Mr. Cotton, Mr. Cramer, Mr. Crapo, Mr. Cruz, Mr. Daines, Ms. Duckworth, Mr. Durbin, Ms. Ernst, Mrs. Feinstein, Mrs. Fischer, Mrs. Gillibrand, Mr. Graham, Mr. Grassley, Mr. Hagerty, Ms. Hassan, Mr. Hawley, Mr. Heinrich, Mr. Hickenlooper, Ms. Hirono, Mr. Hoeven, Mrs. Hyde-Smith, Mr. Inhofe, Mr. Johnson, Mr. Kaine, Mr. Kelly, Mr. Kennedy, Mr. King, Ms. Klobuchar, Mr. Lankford, Mr. Leahy, Mr. Lee, Mr. Luján, Ms. Lummis, Mr. Manchin, Mr. Markey, Mr. Marshall, Mr. Menendez, Mr. Merkley, Mr. Moran, Mr. Murphy, Mrs. Murray, Mr. Ossoff, Mr. Padilla, Mr. Paul, Mr. Peters, Mr. Portman, Mr. Reed, Mr. Risch, Mr. Romney, Ms. Rosen, Mr. Rounds, Mr. Rubio, Mr. Sanders, Mr. Sasse, Mr. Schatz, Mr. Scott of Florida, Mr. Scott of South Carolina, Mrs. Shaheen, Mr. Shelby, Ms. Sinema, Ms. Smith, Ms. Stabenow, Mr. Tester, Mr. Thune, Mr. Tillis, Mr. Toomey, Mr. Tuberville, Mr. Van Hollen, Mr. Warner, Mr. Warnock, Ms. Warren, Mr. Whitehouse, Mr. Wicker, Mr. Wyden, and Mr. Young) submitted the following resolution; which was considered and agreed toRESOLUTIONRelative to the death of the Honorable Maurice Robert Gravel, former Senator from the State of Alaska.Whereas Maurice Robert Gravel was born in Springfield, Massachusetts, and graduated from Columbia University before making his home in Alaska;Whereas Maurice Robert Gravel served in the United States Army from 1951 to 1954;Whereas Maurice Robert Gravel was elected to the Alaska House of Representatives in 1962 and served as Speaker of the House from 1965 to 1966;Whereas Maurice Robert Gravel was elected to the United States Senate in 1968 and served the people of Alaska honorably for 2 terms;Whereas legislation sponsored by Maurice Robert Gravel helped ensure the timely approval and construction of the Trans-Alaska Pipeline System, resulting in decades of economic and other benefits to the State and country; andWhereas Maurice Robert Gravel dedicated his life to public service and passionately advocated for the State of Alaska: Now, therefore, be itThat— (1)the Senate has heard with profound sorrow and deep regret the announcement of the death of the Honorable Maurice Robert Gravel, former Senator from the State of Alaska;(2)the Secretary of the Senate communicate this resolution to the House of Representatives and transmit an enrolled copy thereof to the family of the Honorable Maurice Robert Gravel; and(3)when the Senate adjourns today, it stand adjourned as a further mark of respect to the memory of the Honorable Maurice Robert Gravel.


115 S553 IS: Court Legal Access and Student Support (CLASS) Act of 2017
U.S. Senate
2017-03-07
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

II115th CONGRESS1st SessionS. 553IN THE SENATE OF THE UNITED STATESMarch 7, 2017Mr. Durbin (for himself, Mr. Franken, Mr. Whitehouse, Ms. Warren, Mr. Reed, Mr. Brown, Mr. Blumenthal, and Ms. Hirono) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and PensionsA BILLTo provide that chapter 1 of title 9 of the United States Code, relating to the enforcement of
			 arbitration agreements, shall not apply to enrollment agreements made
			 between students and certain institutions of higher education, and to
			 prohibit limitations on the ability of students to pursue claims against
			 certain institutions of higher education.

 1.Short titleThis Act may be cited as the Court Legal Access and Student Support (CLASS) Act of 2017. 2.Inapplicability of chapter 1 of title 9, United States Code, to enrollment agreements made between students and certain institutions of higher education (a)In GeneralChapter 1 of title 9 of the United States Code (relating to the enforcement of arbitration agreements) shall not apply to an enrollment agreement made between a student and an institution of higher education.
 (b)DefinitionIn this section, the term institution of higher education has the meaning given such term in section 102 of the Higher Education Act of 1965 (20 U.S.C. 1002).
			3.Prohibition on limitations on ability of students to pursue claims against certain institutions of
 higher educationSection 487(a) of the Higher Education Act of 1965 (20 U.S.C. 1094(a)) is amended by adding at the end the following:

 (30)The institution will not require any student to agree to, and will not enforce, any limitation or restriction (including a limitation or restriction on any available choice of applicable law, a jury trial, or venue) on the ability of a student to pursue a claim, individually or with others, against an institution in court..
 4.Effective dateThis Act and the amendments made by this Act shall take effect 1 year after the date of enactment of this Act.


117 HRES 22 EH:
U.S. House of Representatives
2021-01-11
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

IV
117th CONGRESS
1st Session
H. RES. 22
In the House of Representatives, U. S.,

January 11, 2021

RESOLUTION

That the following named Member be, and is hereby, elected to the following standing committee of the House of Representatives: Committee on House Administration:Ms. Lofgren, Chair.

Cheryl L. Johnson,Clerk.


115 S1036 IS: Marine Energy Act
U.S. Senate
2017-05-03
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

		II
		115th CONGRESS1st Session
		S. 1036
		IN THE SENATE OF THE UNITED STATES

			May 3, 2017
			Mr. Wyden (for himself, Mr. King, Mr. Merkley, Mr. Schatz, and Ms. Hirono) introduced the following bill; which was read twice and referred to the Committee on Energy and Natural Resources

		A BILL
		To promote research, development, and demonstration of marine and hydrokinetic renewable energy
			 technologies, and for other purposes.

		1.Short title
 This Act may be cited as the Marine Energy Act.
		2.Definition of
 marine and hydrokinetic renewable energySection 632 of the Energy Independence and Security Act of 2007 (42 U.S.C. 17211) is amended in the matter preceding paragraph (1) by striking electrical.
		3.Marine and
 hydrokinetic renewable energy research and developmentSection 633 of the Energy Independence and Security Act of 2007 (42 U.S.C. 17212) is amended to read as follows:

 633.Marine and hydrokinetic renewable energy research and developmentThe Secretary, in consultation with the Secretary of the Interior, the Secretary of Commerce, and the Federal Energy Regulatory Commission, shall carry out a program of research, development, demonstration, and commercial application to accelerate the introduction of marine and hydrokinetic renewable energy production into the United States energy supply, giving priority to fostering accelerated research, development, and commercialization of technology, including programs—
 (1)to assist technology development to improve the components, processes, and systems used for power generation from marine and hydrokinetic renewable energy resources;
 (2)to establish critical testing infrastructure necessary— (A)to cost effectively and efficiently test and prove marine and hydrokinetic renewable energy devices; and
 (B)to accelerate the technological readiness and commercialization of those devices; (3)to support efforts to increase the efficiency of energy conversion, lower the cost, increase the use, improve the reliability, and demonstrate the applicability of marine and hydrokinetic renewable energy technologies by participating in demonstration projects;
 (4)to investigate variability issues and the efficient and reliable integration of marine and hydrokinetic renewable energy with the utility grid;
 (5)to identify and study critical short- and long-term needs to create a sustainable marine and hydrokinetic renewable energy supply chain based in the United States;
 (6)to increase the reliability and survivability of marine and hydrokinetic renewable energy technologies;
 (7)to verify the performance, reliability, maintainability, and cost of new marine and hydrokinetic renewable energy device designs and system components in an operating environment, and consider the protection of critical infrastructure, such as adequate separation between marine and hydrokinetic devices and projects and submarine telecommunications cables, including consideration of established industry standards;
 (8)to coordinate and avoid duplication of activities across programs of the Department and other applicable Federal agencies, including National Laboratories and to coordinate public-private collaboration in all programs under this section;
 (9)to identify opportunities for joint research and development programs and development of economies of scale between—
 (A)marine and hydrokinetic renewable energy technologies; and (B)other renewable energy and fossil energy programs, offshore oil and gas production activities, and activities of the Department of Defense;
 (10)to support in-water technology development with international partners using existing cooperative procedures (including memoranda of understanding)—
 (A)to allow cooperative funding and other support of value to be exchanged and leveraged; and (B)to encourage the participation of international research centers and companies within the United States and the participation of United States research centers and companies in international projects;
 (11)to identify, in conjunction with the Secretary of Commerce and other relevant Federal agencies, the potential environmental impacts, including potential impacts on fisheries and other marine resources, of marine and hydrokinetic renewable energy technologies, measures to prevent adverse impacts, and technologies and other means available for monitoring and determining environmental impacts; and
 (12)to identify, in conjunction with the Commandant of the United States Coast Guard and other relevant Federal agencies, the potential navigational impacts of marine and hydrokinetic renewable energy technologies and measures to prevent adverse impacts on navigation..
		4.National
			 Marine Renewable Energy Research, Development, and Demonstration
 CentersSection 634 of the Energy Independence and Security Act of 2007 (42 U.S.C. 17213) is amended by striking subsection (b) and inserting the following:

 (b)PurposesThe Centers (including each Center that has been established as of the date of enactment of the Marine Energy Act), in coordination with the Department and the National Laboratories, shall— (1)advance research, development, demonstration, and commercial application of marine and hydrokinetic renewable energy technologies;
 (2)support in-water testing and demonstration of marine and hydrokinetic renewable energy technologies, including facilities capable of testing—
 (A)marine and hydrokinetic renewable energy systems of various technology readiness levels and scales;
 (B)a variety of technologies in multiple test berths at a single location; and
 (C)arrays of technology devices; and
 (3)serve as information clearinghouses for the marine and hydrokinetic renewable energy industry by collecting and disseminating information on best practices in all areas relating to developing and managing marine and hydrokinetic renewable energy resources and energy systems..
		5.Authorization
 of appropriationsSection 636 of the Energy Independence and Security Act of 2007 (42 U.S.C. 17215) is amended by striking $50,000,000 for each of the fiscal years 2008 through 2012 and inserting $60,000,000 for each of fiscal years 2018 through 2022.